New corporate presentation out....
Pretty much everything we knew already, but, under "OTHER PRONEURA OPPORTUNITIES Feasibility Evaluations" we find:
• Treatment of Type 2 diabetes with currently approved peptides
---(We knew this already...liraglutide (Victoza), which is off patent so TTNP can pursue the 505(b)(2) pathway)
• Treatment of peripheral neuropathic pain with a Kappa opioid receptor agonist
• Treatment of opioid addiction with a Mu opioid receptor antagonist
---(These two are new! Given management's statement that it will only pursue opportunities with immediate funding available, they likely represent potential partnerships).
News 
Market Data 
Discover 
AI
